The Board of Directors of CSL Limited announced that it has appointed Dr. Paul McKenzie as Managing Director of the company from 6 March 2023. Dr. McKenzie will succeed Mr. Paul Perreault, who has advised the Board of his intention to retire after serving 10 years in the role, and more than 25 years with the company. Dr. McKenzie has been appointed following a thorough process conducted by the Board.

Currently serving as CSL's Chief Operating Officer (COO), Dr. McKenzie, will immediately join the Board of Directors as an Executive Director and will become CEO and Managing Director on 6 March 2023. Mr. Perreault will step down from the CSL Board of Directors on 6 March 2023 and he will remain with the company as a strategic adviser to assist in an orderly transition until he retires on 6 September 2023. Dr. McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organizations through compelling growth and transformation.

Since joining CSL as COO in 2019, Dr. McKenzie has been accountable for optimising CSL's operations as well as growing the CSL Seqirus, CSL Plasma, and CSL Vifor businesses. He transformed CSL's global end-to-end operations, advanced CSL Seqirus' differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. Prior to joining CSL, Dr McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen.

He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck. Paul McKenzie, who earned his PhD in engineering, was appointed CSL's Chief Operating Officer in June 2019. The role of Chief Operating Officer includes responsibility for CSL Seqirus, CSL Plasma, CSL Vifor businesses as well as CSL's manufacturing, quality, engineering, environment, health & safety, supply chain and procurement.

Paul is an accomplished global leader with diverse biotechnology experience across the industry. Prior to joining CSL, he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen where he was responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering. With more than 30 years of experience, Paul also held various senior roles in R&D and manufacturing for Johnson & Johnson, Bristol-Myers Squibb and Merck.

Paul was elected to the National Academy of Engineering in 2020. He has served on numerous professional and academic boards, most recently the Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering. Paul holds a B.S. in Chemical Engineering from the University of Pennsylvania and a Ph.D. in Chemical Engineering from Carnegie Mellon University.

Career history: 2019 – present Chief Operating Officer CSL; 2016 - 2019: Executive Vice President of Pharmaceutical Operations & Technology, Biogen; 2008 – 2016: Johnson & Johnson;1998 – 2008: Bristol-Myers Squibb; 1992 – 1998: Merck.